Wednesday, March 29, 2023


Biotechnology News Magazine


Merck KGaA, Darmstadt, Germany Showcases Depth of MS Portfolio at ECTRIMS Supporting Commitment to Advancing MS Care

Merck KGaA, Darmstadt, Germany today announced it will present 39 abstracts at the 38thCongress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), being held October 26-28, 2022 in Amsterdam, the Netherlands.

Aptar Digital Health Launches New Digital Disease Management Platform to Better Track Patient Treatment Adherence

This new platform expands Aptar Pharma's portfolio of digital health solutions with a complete, end-to-end solution, supporting patients from the prevention and diagnosis phases, to disease management, and more, across multiple therapeutic areas.

Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients

Calyxt advises that the agreement will power speed-to-scale strategy to meet the growing interest in high-quality sustainable ingredients across the cosmeceutical, nutraceutical and pharmaceutical markets

Provention Bio to Combine Forces with Sanofi to Support Potential U.S. Launch of Teplizumab for Delay in Onset of Clinical Type 1 Diabetes (T1D)...

The agreement enables Provention Bio to leverage Sanofi's expertise, capabilities and commercial resources to support the potential launch of teplizumab currently under review by the U.S. Food and Drug Administration ("FDA"), for the delay of clinical type 1 diabetes in at-risk individuals, with a user fee goal date of November 17, 2022 for the Biologics License Application.

Panaxia and Neuraxpharm to Enter New Medical Cannabis Markets in Europe

Neuraxpharm notes the collaboration includes the marketing and distribution of advanced medical cannabis products, including cannabis extracts for inhalation, produced by Panaxia.

Development of New Drugs to Target Lyme and Other Infectious Diseases Subject of a New Webinar Now Available From Quidel Corporation

Lyme disease is the fastest-growing vector-borne disease in the United States, and its increased prevalence is challenging the scientific community to look for new ways to diagnose and treat this worrisome infection.